210.50
+3.47(+1.68%)
Currency In USD
| Previous Close | 207.03 |
| Open | 208.25 |
| Day High | 214.47 |
| Day Low | 206.02 |
| 52-Week High | 216.45 |
| 52-Week Low | 118.03 |
| Volume | 444,453 |
| Average Volume | 465,782 |
| Market Cap | 12.75B |
| PE | -39.87 |
| EPS | -5.28 |
| Moving Average 50 Days | 199.1 |
| Moving Average 200 Days | 167.25 |
| Change | 3.47 |
If you invested $1000 in Ascendis Pharma A/S (ASND) 10 years ago, it would be worth $11,805.95 as of October 19, 2025 at a share price of $210.5. Whereas If you bought $1000 worth of Ascendis Pharma A/S (ASND) shares 5 years ago, it would be worth $1,344.45 as of October 19, 2025 at a share price of $210.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
GlobeNewswire Inc.
Oct 08, 2025 8:01 PM GMT
COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon CNP (navepegritide) as a trea
Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025
GlobeNewswire Inc.
Sep 02, 2025 8:01 PM GMT
COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the American Society f
Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference
GlobeNewswire Inc.
Aug 28, 2025 8:01 PM GMT
COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at